Secretary Kennedy Surrenders Patient Data to Big Pharma

Health and Human Services Secretary Robert F. Kennedy Jr. built a political brand as a maverick ready to take on the pharmaceutical cartel. But that rhetoric has evaporated, replaced by a pattern of capitulation. In his latest abdication of duty, Secretary Kennedy is allowing drug manufacturers to extract detailed patient data from hospitals and clinics.

Big Pharma is now demanding that safety-net providers hand over sensitive, claims-level patient data, coercing providers into a compliance trap under the threat of losing life-saving discounts under the 340B Drug Discount Program.

For more than 30 years, drug companies seeking to verify compliance have followed an audit process overseen by the Health Resources and Services Administration. Now manufacturers are bypassing the agency entirely and demanding sensitive data directly from safety-net providers as a precondition for receiving the 340B pricing to which they are legally entitled.

Major manufacturers like Amgen are instituting draconian mandates forcing providers to surrender detailed information on patient diagnoses, billing records, dates of service, and specific healthcare settings, expanding their demands to include even in-house pharmacy use and clinical service data. This is not routine bookkeeping. It is a calculated assault on healthcare providers with one goal: denying discounts.

This corporate overreach follows the blueprint laid out by Eli Lilly which shocked safety-net providers by demanding extensive claims-level data for all in-house pharmacy prescriptions and threatening hospitals with the “imminent loss” of discounted pricing if they failed to comply. Pharma executives regularly invoke the tired bogeyman of “duplicate discounts”—the idea that a drug receives both a 340B reduction and a Medicaid rebate—to justify their intrusion. But if this were truly about Medicaid compliance, why are these broad data requests targeting all prescriptions, regardless of whether a patient is enrolled in Medicaid?

The most disturbing aspect of this corporate overreach is the total complicity of HHS leadership. It is incomprehensible that a health secretary who claims to fight corporate corruption cannot find an ounce of concern for safety-net hospitals or the wholesale transfer of patient medical data to private drug companies. What are these corporations doing with this data? Why should they have unfettered, direct access to private patient information?

It gets worse. While Secretary Kennedy allows drug companies to run wild, his department is actively working to dismantle 340B protections at the state level. In ongoing federal court battles across the country, HHS and the Department of Justice have repeatedly sided with pharmaceutical companies, filing legal briefs seeking to strike down state laws in Colorado, Rhode Island, and Louisiana that were explicitly enacted to protect the 340B benefits of local clinics and community pharmacies.

This is pure betrayal. The man who promised to disrupt the pharmaceutical industry has gone native, becoming a facilitator for Big Pharma’s anti-340B agenda. We believe Mr. Kennedy hopes no one notices that he is quietly supporting a regime that decimates the financial lifelines of safety-net providers. Rural hospitals are at particular risk.

Mr. Kennedy is not fighting Big Pharma; he is coddling it. And America’s most vulnerable patients will pay the price.